Influenza vaccine supplier Seqirus revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for AFLURIA QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older as well as the trivalent formulation of AFLURIA (Influenza Vaccine).

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. To reduce the risk of more serious influenza-related outcomes, such as hospitalisation and death, the CDC encourages annual vaccination for all individuals aged 6 months and older.

Following the US FDA approval, the AFLURIA QUADRIVALENT is available in the US in pre-filled syringes as well as multi-dose vials for the 2018-2019 influenza season, according to the company.

In August 2016, the AFLURIA QUADRIVALENT was first approved in the US for adults aged 18 years and above and helps protect against two influenza A strain viruses and two B strain viruses, added the company.

Additionally, the AFLURIA (Influenza Vaccine) is a trivalent influenza vaccine developed with egg-based technologies and is indicated for persons aged five or older. It is available in both prefilled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it. It is the only trivalent flu vaccine with a needle-free delivery option for persons 18 through 64 years of age, concluded the company.